Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Concentrix (CNXC) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Concentrix (CNXC) over the last 6 years, with Q4 2025 value amounting to $327.3 million.

  • Concentrix's Cash & Equivalents rose 3607.08% to $327.3 million in Q4 2025 from the same period last year, while for Nov 2025 it was $327.3 million, marking a year-over-year increase of 3607.08%. This contributed to the annual value of $327.3 million for FY2025, which is 3607.08% up from last year.
  • Per Concentrix's latest filing, its Cash & Equivalents stood at $327.3 million for Q4 2025, which was up 3607.08% from $350.3 million recorded in Q3 2025.
  • In the past 5 years, Concentrix's Cash & Equivalents registered a high of $2.1 billion during Q3 2023, and its lowest value of $119.2 million during Q1 2021.
  • Moreover, its 5-year median value for Cash & Equivalents was $195.2 million (2021), whereas its average is $311.3 million.
  • As far as peak fluctuations go, Concentrix's Cash & Equivalents soared by 109989.1% in 2023, and later tumbled by 8834.52% in 2024.
  • Concentrix's Cash & Equivalents (Quarter) stood at $183.0 million in 2021, then dropped by 13.96% to $157.5 million in 2022, then soared by 87.56% to $295.3 million in 2023, then dropped by 18.54% to $240.6 million in 2024, then soared by 36.07% to $327.3 million in 2025.
  • Its Cash & Equivalents stands at $327.3 million for Q4 2025, versus $350.3 million for Q3 2025 and $342.8 million for Q2 2025.